Form 4: Insmed CEO William Lewis Executes Stock Option and Sells Shares Under 10b5-1 Plan

Insmed's CEO, William Lewis, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on March 3, 2025.

Summary

• On March 3, 2025, William Lewis, the Chair and CEO of Insmed Inc., executed stock options and sold shares of Insmed common stock.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan.
• Lewis exercised options to acquire 18,750 shares at $22.76 per share and 6,830 shares at $10.85 per share.
• He sold a total of 19,446 shares directly at prices ranging from $76.24 to $80.90.
• He also sold shares held by the Katie Procter Dynasty Trust, totaling 6,784 shares, at prices ranging from $76.23 to $80.90.
• Following these transactions, Lewis directly owns 334,186 shares of common stock.
• He also indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
• The options exercised became exercisable based on a vesting schedule, with 25% vesting on the first anniversary of the grant date and an additional 12.5% vesting every six months thereafter through the fourth anniversary.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Executive stock transactions are common and often pre-planned to comply with insider trading regulations. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The vesting schedule described is typical for stock options granted to executives.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings and avoid insider trading concerns.
• Comparable companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Regeneron Pharmaceuticals also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The stock sales could have a minor impact on the stock price, depending on market perception.
• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.

Key Dates